ADAURA and the Evolving Role of Targeted Therapy

Episode
155
Soundcloud
Share

Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu talk with Dr. Roy Herbst about the ADAURA Trial.  ADAURA introduced targeted therapy in the adjuvant setting for early-stage EGFR-positive NSCLC. While we have seen targeted therapy in this space, ADAURA showed DFS rates never seen before and changed the treatment of early-stage lung cancer.

Guest
Stephen Liu
Stephen Liu

MD

Chief of Hematology and Oncology, Associate Professor of Medicine
Georgetown University Hospital
Lombardi Comprehensive Cancer Center
Narjust Florez
Narjust Florez

MD

Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School